Search Results
Your search for The ASCO matches 21099 pages
Showing 11301 - 11350FDA Approves Dabrafenib Plus Trametinib for Adjuvant Treatment of Melanoma With BRAF V600E or V600K Mutations
On April 30, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to dabrafenib (Tafinlar) and trametinib (Mekinist) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations (as detected by an FDA-approved test) and involvement of...
Update Regarding Tazemetostat Clinical Program
On April 23, Epizyme, Inc, announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report of a pediatric patient who developed a secondary lymphoma, the U.S. Food and Drug Administration (FDA) issued a partial clinical hold...
Results From Phase III RANGE Study of Ramucirumab in Advanced or Metastatic Urothelial Cancer
Eli Lilly and Company recently announced additional results from its global, randomized, double-blind, placebo-controlled phase III RANGE trial evaluating ramucirumab (Cyramza) in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma whose...
Many Economic Evaluations of Oncotype DX May Have Misleading Conclusions
Research from the Yale School of Public Health has found that the majority of published papers analyzing the cost-effectiveness of a widely used test for breast cancer used a study design that can increase bias. These findings were published by Wang et al in the Journal of Clinical Oncology....
Roy Herbst, MD, PhD, on Legal and Policy Issues Associated With Cutting-Edge Cancer Treatments
Roy Herbst, MD, PhD, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, speaks during Panel 5: Legal and Policy Issues Associated With Cutting-Edge Cancer Treatments at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale...
Hematology Fellows and Junior Faculty Participate in 2018 ASH Clinical Research Training Institute in Latin America
This week, the American Society of Hematology (ASH) announced the names of the 35 hematologists participating in the 2018 ASH Clinical Research Training Institute in Latin America (CRTI-LA) and Advanced CRTI-LA. This education and mentorship program was held April 23–26, prior to the...
ESTRO 37: Positioning for Radiotherapy and Impact on Survival in Patients With Lung or Esophageal Cancers
Very small differences in the way a patient lies during radiotherapy treatment for lung or esophageal cancer can have an impact on survival, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract OC-0322). These differences of only a...
ESTRO 37: Ultrahypofractionated Radiotherapy for Prostate Cancer Is Safe and Effective
Radiotherapy given in high doses over a shorter period of time is safe and effective for patients with prostate cancer, according to research from a phase III trial presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract OC-0599). The...
ESTRO 37: Handgrip Strength Test May Be a Good Indicator of Survival in Patients With NSCLC
A simple test of handgrip strength may be a good indicator of short- and long-term survival in patients with stage I non–small cell lung cancer (NSCLC), according to new findings presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract PV0041)....
ESTRO 37: Elderly Patients With NSCLC May Be Less Likely to Benefit From Concurrent Chemoradiotherapy
An analysis of elderly patients with non–small cell lung cancer (NSCLC) treated in a phase II trial of radiotherapy combined with chemotherapy has shown that they were less likely to benefit than younger patients if the two treatments were given at the same time. These findings were presented ...
ESTRO 37: Brachytherapy for Patients With Cervical Cancer Does Not Increase Risk of Ureteral Stricture
A rare but potentially serious complication following radiation treatment for cervical cancer is a narrowing of the tube that takes urine from the kidneys to the bladder (the ureter), which can lead to kidney damage and sometimes life-threatening infections. This is called ureteral stricture and,...
Link Between Risk of Alzheimer’s Disease and Melanoma, Nonmelanoma Skin Cancers
Although literature demonstrates a decreased risk of Alzheimer's disease in individuals with various cancers—including squamous cell cancers (SCC) and basal cell cancers (BCC)—there is a paucity of literature to substantiate an association between malignant melanoma and...
Pediatric Centers May Improve Survival for Adolescents and Young Adults With ALL
Adolescents and young adults (AYAs) with acute lymphocytic leukemia (ALL) have a survival advantage if they receive treatment at a pediatric cancer center vs an adult center, according to a study published by Muffly et al in Blood Advances. The findings also suggest that treatment at a center...
FDA Accepts sBLA, Grants Priority Review for Nivolumab in Previously Treated Patients With SCLC
On April 18, the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental biologics license application (sBLA) for nivolumab (Opdivo) to treat patients with small cell lung cancer (SCLC) whose disease has progressed after two or more prior lines of therapy. ...
ASCO Remembers Patient Advocate Karen Durham
ASCO AND THE ONCOLOGY COMMUNITY mourn the loss of Karen Durham, who passed away on March 26, 2018, in Tyler, Texas. Karen was a highly respected and beloved advocate for people living with cancer. Karen was diagnosed with stage II invasive breast cancer in 1989 and began volunteering with Susan...
Cooperative Group Trial Pioneer Dr. James F. Holland Dies at 92
ASCO AND THE ONCOLOGY COMMUNITY are deeply saddened by the loss of James F. Holland, MD, FASCO, who passed away on March 22, 2018. He was 92. Dr. Holland was a Distinguished Professor of Neoplastic Diseases in the Department of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at...
Neuroendocrine Tumor Research Foundation Awards Six Research Grants
THE NEUROENDOCRINE Tumor Research Foundation (NETRF) has awarded six new research grants, totaling about $1.85 million, to leading academic institutions around the world. The grants fund clinical, translational, and basic research in the United States, Australia, Switzerland, and the United...
Fabrice Barlesi, MD, PhD, Receives 2018 Heine H. Hansen Award
THE EUROPEAN SOCIETY for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen Award was given to Fabrice Barlesi, MD, PhD. The award was presented at the 2018 European Lung Cancer Congress (ELCC 2018) in early...
Massage Therapy for Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, reviews the current data on the use of massage to...
Cancer Cost Planning and Accounting for Patients Under 65
A new study published by Banegas et al in JNCCN–Journal of the National Comprehensive Cancer Network has found that cancer care costs in the United States are higher for people under age 65—and that costs increase with disease stage. Despite the fact that nearly half of new cancer...
CB-839 in Combination With Cabozantinib for Advanced RCC Granted FDA Fast Track Designation
On April 18, Calithera Biosciences, Inc, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CB-839 in combination with cabozantinib (Cabometyx) for the treatment of patients with metastatic renal cell carcinoma (RCC) who have received one or two prior lines ...
FDA Grants Fast Track Designation for Balixafortide in Combination With Eribulin as Third-Line Therapy for Metastatic Breast Cancer
On April 19, Polyphor announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326) in combination with eribulin (Halaven) for the treatment of patients with HER2-negative metastatic breast cancer who...
Updated International Myeloma Working Group Criteria: Diagnostic Challenges
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for...
Barbara McAneny, MD, on The Business of Cancer
Barbara McAneny, MD, Co-Founder and CEO, New Mexico Oncology Hematology Consultants; President-Elect, American Medical Association, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School,...
Follicular Extension in Actinic Keratosis and Invasion in Squamous Cell Carcinoma
Actinic keratoses may show extension down into follicles, not only in cases with full-thickness epidermal atypia (bowenoid actinic keratosis), but also in cases with atypia limited to the epidermal basalis. Previous studies have demonstrated that, in bowenoid actinic keratosis, follicular...
COA Practice Impact Report Details Consolidation, Shift of U.S. Cancer Care System Into More Expensive Hospital Setting
The Community Oncology Alliance (COA) has released the 2018 Community Oncology Practice Impact Report, which tracks data on the changing landscape of cancer care in the United States. It details a decade-long trend of closure and consolidation in the U.S. cancer system that has resulted in a...
Personalized Tumor Vaccine Shows Promise in Advanced Ovarian Cancer
A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania. The personalized vaccine is made from a patient’s own immune ...
St. Jude Cloud, Largest Public Repository of Pediatric Cancer Genomics Data, Launches for Researchers Worldwide
On April 12, St. Jude Children’s Research Hospital launched the St. Jude Cloud, an online data-sharing and collaboration platform that provides researchers access to the world's largest public repository of pediatric cancer genomics data. Developed as a partnership among St. Jude,...
FDA Unveils Streamlined Path for Authorizing Tumor-Profiling Tests Alongside Its Latest Product Action
The U.S. Food and Drug Administration (FDA) recently finalized two guidances to drive the efficient development of next-generation sequencing, which scans a person’s DNA to diagnose genetic diseases, and guide medical treatments. The guidances provide recommendations for designing,...
Update on ATLAS Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
ASCO Clinical Practice Guideline Update: Fertility Preservation in Patients With Cancer
As reported in the Journal of Clinical Oncology by Kutluk Oktay, MD, PhD, of Yale University School of Medicine, and colleagues, ASCO has issued a clinical practice guideline update on fertility preservation in adults and children with cancer. The update was informed by an update panel systematic...
FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations
On April 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
Norman Sharpless, MD: Keynote Address
Norman Sharpless, MD, Director, National Cancer Institute, presents the Keynote Address at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and Yale Cancer Center.
Siddhartha Mukherjee, MD, DPhil: Keynote Address
Siddhartha Mukherjee, MD, DPhil, Assistant Professor of Medicine, Columbia University Medical Center, presents the Keynote Address at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital...
Charles Sawyers, MD, on Legal and Policy Issues Associated With Cutting-Edge Cancer Treatments
Charles Sawyers, MD, Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, speaks during Panel 5: Legal and Policy Issues Associated With Cutting-Edge Cancer Treatments at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and...
Peter Bach, MD, MAPP, on Drug Development and the Cost of Researching and Treating Cancer
Peter Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, speaks during Panel 4: Drug Development and the Cost of Researching and Treating Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and...
Amy Kapczynski, JD, on Drug Development and the Cost of Researching and Treating Cancer
Amy Kapczynski, JD, Professor of Law and Faculty Director, Global Health Justice Partnership, Yale Law School, speaks during Panel 4: Drug Development and the Cost of Researching and Treating Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy ...
Jeffrey Schwartz, MBA, on Drug Development and the Cost of Researching and Treating Cancer
Jeffrey Schwartz, MBA, Managing Director, Bain Capital Life Sciences, speaks during Panel 4: Drug Development and the Cost of Researching and Treating Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration...
Levi Garraway, MD, PhD, on Drug Development and the Cost of Researching and Treating Cancer
Levi Garraway, MD, PhD, Senior Vice President, Global Development & Medical Affairs, Eli Lilly, speaks during Panel 4: Drug Development and the Cost of Researching and Treating Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale...
Deborah Schrag, MD, MPH, on Cancer, Health Justice, and Disparities
Deborah Schrag, MD, MPH, Chief, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The...
Blase Polite, MD, on Cancer, Health Justice, and Disparities
Blase Polite, MD, Associate Professor of Medicine, University of Chicago Medical Center, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with...
Otis Brawley, MD, on Cancer, Health Justice, and Disparities
Otis Brawley, MD, Chief Medical Officer, American Cancer Society, speaks during Panel 3: Cancer, Health Justice, and Disparities at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and...
Lee Newcomer, MD, MHA, on The Business of Cancer
Lee Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics and Women’s Health, UnitedHealthcare, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
Randall Oyer, MD, on The Business of Cancer
Randall Oyer, MD, Medical Director, Oncology Program, Lancaster General Hospital, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and...
Ed Benz, MD, on The Business of Cancer
Ed Benz, MD, President and CEO Emeritus, Dana-Farber Cancer Institute, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and Yale Cancer...
Abe Lopman, MBA, on The Business of Cancer
Abe Lopman, MBA, Senior Vice President, Operations; Executive Director, Smilow Cancer Hospital at Yale New Haven, speaks during Panel 2: The Business of Cancer at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration...
Richard Schilsky, MD: Is the Federal Government a Productive Partner in Cancer Policy?
Richard Schilsky, MD, Chief Medical Officer, ASCO, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer...
Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer
A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...
Pembrolizumab Monotherapy in NSCLC Meets Primary Endpoint in Phase III KEYNOTE-042 Study
On April 9, the phase III KEYNOTE-042 trial evaluating pembrolizumab (Keytruda) as monotherapy for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS). An ...
Nancy Goodman, JD, MPP: Is the Federal Government a Productive Partner in Cancer Policy?
Nancy Goodman, JD, MPP, Executive Director, Kids V Cancer, speaks during Panel 1: Is the Federal Government a Productive Partner in Cancer Policy? at The Policy, Politics and Law of Cancer, presented by The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow...
